Animals might have to be tested for residue levels if an injection site lesion is detected at post mortem examination.

Section 20(3)(a) of the Animal Products Act 1999 (“the Act”) empowers the Director-General of MPI to waive or modify the requirement that an application to register a risk management programme must be accompanied by an independent evaluation report where the proposed programme is fully based on a template, model or code of practice approved under section 12(3A) of the Act.